New hope for rare kidney cancer: dual immunotherapy trial seeks better control
NCT ID NCT05347212
Summary
This study is testing whether a combination of two immunotherapy drugs, nivolumab and relatlimab, can help control advanced renal medullary carcinoma (RMC), a rare and aggressive type of kidney cancer. The trial will enroll about 30 adults whose cancer has spread or cannot be removed by surgery. The main goal is to see if this drug combination shrinks tumors better than standard chemotherapy has in the past.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.